AUTL
$3.58
Autolus Therapeutics Plc ADR
($.07)
(1.92%)
AUTL
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus:  ($0.45)
Revenue:  $0.24 Mil
Thursday
Nov 3
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AUTL reports earnings?
Beat
Meet
Miss

Where is AUTL's stock price going from here?
Up
Flat
Down
Stock chart of AUTL
Analysts
Summary of analysts' recommendations for AUTL
Score
Grade
Pivots
Resistance
$3.94
$3.85
$3.71

$3.62

Support
$3.48
$3.39
$3.25
Tweet
Growth
Description
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom.